Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer

BACKGROUND: Erlotinib is a highly active EGFR kinase inhibitor approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests this drug may provide continued disease control following objective progression of disease (PD), however this has not been systematically...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer
Huvudupphovsmän: Lo, Peter C., Dahlberg, Suzanne E., Nishino, Mizuki, Johnson, Bruce E., Sequist, Lecia V., Jackman, David M., Jänne, Pasi A, Oxnard, Geoffrey R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4525718/
https://ncbi.nlm.nih.gov/pubmed/25876525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29397
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk